Navigation Links
Genetics May Determine Antidepressants' Effectiveness
Date:1/23/2008

German researchers identify 11 variants that seem to influence outcome

WEDNESDAY, Jan. 23 (HealthDay News) -- Genetic variations that predict patient response to the two common antidepressant drugs citalopram (brand name Celexa) and venlafaxine (Effexor) have been identified by German researchers.

The team at the Max Planck Institute of Psychiatry in Munich found that 11 variants in the gene for a protective transporter protein called P-gp, which removes drugs and other substances from the brain, compromise the effectiveness of these two drugs.

In the first part of the study, the researchers knocked out genes for P-gp in mice and gave them antidepressants. They found that brain concentrations of citalopram and venlafaxine were regulated by P-gp, indicating that the antidepressants were "substrates" of the transporter protein.

Next, the team analyzed 443 people on antidepressants for genetic variants that correlated with reduced efficacy of the two antidepressants.

"To our knowledge, our results provide for the first time evidence that genetic variants in the (gene for P-gp) account for differences in the clinical efficacy of antidepressants, most likely by influencing their access to the brain," the researchers wrote.

The findings, published in the Jan. 24 issue of the journal Neuron, suggest that genetic testing could help predict how individual patients would react to specific antidepressants, the researchers said.

They added that genetic tests may also help predict the effectiveness of any drugs used to treat neurological diseases.

"The general conclusion to be drawn is that any drug treatment administered to treat CNS (central nervous system) diseases should be analyzed for its P-gp substrate status, which can be determined by using knockout mice. From a clinical point of view, the findings warrant that patients receiving a drug that is a P-gp substrate for the treatment of brain diseases are genotyped to exclude the possibility that a patient receives a drug that fails to enter the CNS to an extent required for efficacy," the study authors wrote.

Future development of antidepressants should take into account whether new drugs are transported by P-gp, and clinical trials of antidepressant drugs need to factor in the P-gp genetic status of participants, the researchers recommended.

More information

The U.S. National Institute of Mental Health has more about depression.



-- Robert Preidt



SOURCE: Cell Press, news release, Jan. 23, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetics Influence Blood Pressure Medications
2. People with anorexia less likely to be blamed when biology, genetics explained
3. Top10 research advances include studies on genetics and stem cell research, stents
4. Heart attack risk from smoking due to genetics
5. Genetics May Boost Mexican-Americans Risk for Alcoholism
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
7. Researchers develop powerful tool to study the genetics of inflammation
8. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
10. Genetics and Risk, This Week on Your Cancer Today(TM)
11. CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetics May Determine Antidepressants' Effectiveness
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology: